REGULATORY

Chuikyo to Discuss Annual Price Revision Plan in Concert with CEFP: Official

December 22, 2016

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Future agenda items for the introduction of annual price revisions will be discussed by the health ministry’s Central Social Insurance Medical Council (Chuikyo) in coordination with the Council on Economic and Fiscal Policy (CEFP), Prime Minister Shinzo Abe’s key advisory…

To read the full story

PM Abe’s Panel to Keep Vigilant Eyes on Drug Prices, Reimbursement Fees
December 22, 2016
Four Ministers Map Out Basic Policy for Drug Pricing Revamp
December 21, 2016
Basic Policy for Drastic Reform of Drug Pricing System
December 20, 2016

REGULATORY

Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026
PMDA Eyes AI as Staffing Shortages Affect Orphan Drug Reviews
June 25, 2026
Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…